Article
Unique epigenomic signatures identify biologically significant subtypes of MDS and predict response to azacitidine
2025-04-26
Abstract excerpt
Myelodysplastic syndromes (MDS) are characterized by aberrant DNA methylation, and mutations in epigenetic modifiers are frequently found in these patients. Although DNA methyltransferase inhibitors (DNMTi) are used to treat MDS, response variability remains a challenge in the clinic, with limited predictive markers. Through comprehensive genomic, epigenomic, and transcriptomic analyses, we have gained valuable in...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 70f2a3b2-3c62-5709-8cb8-de0d422ebc19
- DOI
- 10.1101/2025.04.23.650336